Chikungunya VLP  

Chikungunya virus-like particles (VLPs) are non-infectious, self-assembled structures that closely resemble the chikungunya virus (CHIKV). These VLPs lack viral RNA, making them safe and effective tools for vaccine development, immunological research, and therapeutic applications. CHIKV, an arbovirus transmitted by Aedes mosquitoes, causes chikungunya fever, characterized by fever, rash, and severe joint pain.

Structure of Chikungunya VLPs

Chikungunya VLPs are primarily composed of the virus's structural proteins:

  • Capsid protein (C): Encapsulates the viral genome in native CHIKV, but forms the core structure in VLPs.
  • Envelope glycoproteins (E1 and E2): Embedded in the lipid membrane, these glycoproteins are critical for host cell attachment and fusion. They are the primary targets of neutralizing antibodies.
Production Systems

Chikungunya VLPs can be expressed in various host systems:

  • Insect Cells (e.g., baculovirus expression system): Ensures proper folding and glycosylation of envelope proteins.
  • Mammalian Cells: Produces VLPs with post-translational modifications similar to native CHIKV.
  • Plant-Based Systems: Emerging as a cost-effective and scalable alternative.
Applications
  • Vaccines
    • Prophylactic Vaccines: Chikungunya VLP-based vaccines elicit robust immune responses, including neutralizing antibodies against E1 and E2 proteins.
    • Pandemic Preparedness: VLP platforms can be rapidly adapted for new outbreaks of CHIKV.
  • Immunological Research
    • Used to study CHIKV pathogenesis and the immune response to structural proteins, especially the mechanisms of neutralization.
  • Diagnostics
    • Chikungunya VLPs are employed as antigens in serological assays for detecting CHIKV-specific antibodies in patient samples.
  • Therapeutic Development
    • Explored as carriers for delivering antiviral drugs or other therapeutic molecules targeting CHIKV.

Chikungunya VLPs represent a powerful platform for combating chikungunya virus infections. With their safety, rapid production potential, and strong immunogenicity, they hold promise for use in vaccines, diagnostics, and therapeutic research. Ongoing advancements in VLP technology aim to make them a cornerstone of global health efforts against CHIKV.

3,962.47 3962.4700000000003 USD
6,894.92 6894.92 USD
1,286.93 1286.93 USD